Ohtsuka Tsutomu
Department of Dermatology, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan.
Int J Dermatol. 2015 Jun;54(6):648-55. doi: 10.1111/ijd.12374. Epub 2014 Oct 14.
Many patients with atopic dermatitis (AD) are treated with oral cyclosporine or antihistamine therapy in clinical practice.
To evaluate the effectiveness of oral cyclosporine and antihistamine therapy on clinical and laboratory findings in patients with AD.
Twenty-five patients with AD (male-female = 11 : 14, age 16-42 years old, mean 26.2 years old) were treated with oral cyclosporine therapy. Twenty-three patients with AD (male-female = 10 : 13, age 15-32 years old, mean 24.2 years old) were treated with oral antihistamine therapy. Laboratory findings including high-sensitivity C-reactive protein (CRP) and thymus and activation-regulated chemokine (TARC) were statistically studied.
Serum TARC level after oral cyclosporine therapy (1013 ± 883 pg/ml) was significantly decreased compared to before therapy (38 194 ± 4678 pg/ml; P < 0.02). Basophil counts in peripheral blood after the therapy (49.7 ± 26.4 × 10(-3) cells/μl) were more significantly increased than before therapy (41.1 ± 16.7 × 10(-3) cells/μl; P < 0.05). Serum high-sensitivity CRP level after antihistamine therapy (0.09 ± 0.08 mg/ml) was significantly decreased compared to before therapy (0.13 ± 0.12 mg/ml; P < 0.05). Basophil counts in peripheral blood after the therapy (33.4 ± 16.2 × 10(-3) cells/μl) were more significantly decreased than before therapy (41.5 ± 23.3 × 10(-3) cells/μl; P < 0.01).
Different effects of oral cyclosporine therapy and oral antihistamine therapy to serum high-sensitivity CRP level, TARC level, and peripheral blood basophils in adult patients with AD were shown. A combination of these two therapies may be more effective for the treatment of AD in adults.
在临床实践中,许多特应性皮炎(AD)患者接受口服环孢素或抗组胺药治疗。
评估口服环孢素和抗组胺药治疗对AD患者临床及实验室检查结果的有效性。
25例AD患者(男∶女 = 11∶14,年龄16 - 42岁,平均26.2岁)接受口服环孢素治疗。23例AD患者(男∶女 = 10∶13,年龄15 - 32岁,平均24.2岁)接受口服抗组胺药治疗。对包括高敏C反应蛋白(CRP)和胸腺活化调节趋化因子(TARC)在内的实验室检查结果进行统计学研究。
口服环孢素治疗后血清TARC水平(1013 ± 883 pg/ml)较治疗前(38194 ± 4678 pg/ml;P < 0.02)显著降低。治疗后外周血嗜碱性粒细胞计数(49.7 ± 26.4× (10^{-3}) 个/μl)较治疗前(41.1 ± 16.7× (10^{-3}) 个/μl;P < 0.05)显著升高。抗组胺药治疗后血清高敏CRP水平(0.09 ± 0.08 mg/ml)较治疗前(0.13 ± 0.12 mg/ml;P < 0.05)显著降低。治疗后外周血嗜碱性粒细胞计数(33.4 ± 16.2× (10^{-3}) 个/μl)较治疗前(41.5 ± 23.3× (10^{-3}) 个/μl;P < 0.01)显著降低。
显示出口服环孢素治疗和口服抗组胺药治疗对成年AD患者血清高敏CRP水平、TARC水平及外周血嗜碱性粒细胞有不同影响。这两种疗法联合使用可能对成年AD患者的治疗更有效。